Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy
- 1 February 2009
- journal article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 123 (2), 459-465
- https://doi.org/10.1016/j.jaci.2008.12.024
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- CCL2 Increases X4-tropic HIV-1 Entry into Resting CD4+ T CellsPublished by Elsevier BV ,2008
- The spread, treatment, and prevention of HIV-1: evolution of a global pandemicJCI Insight, 2008
- Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitroAntiviral Research, 2008
- Induction of apoptosis by epigallocatechin-3-gallate in human lymphoblastoid B cellsBiochemical and Biophysical Research Communications, 2007
- Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapyJournal of Allergy and Clinical Immunology, 2006
- Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implicationsBlood, 2006
- Dual function of (−)-epigallocatechin gallate (EGCG) in healthy human lymphocytesCancer Letters, 2005
- Epigallocatechin gallate induces apoptosis of monocytesJournal of Allergy and Clinical Immunology, 2004
- GREEN TEA (CAMELLIA SINENSIS) EXTRACT DOES NOT ALTER CYTOCHROME P450 3A4 OR 2D6 ACTIVITY IN HEALTHY VOLUNTEERSPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Mitogenic activity of (−)epigallocatechin gallate on B-cells and investigation of its structure-function relationshipInternational Journal of Immunopharmacology, 1992